EP Patent

EP3598134A1 — Methods of treatment with taselisib

Assigned to F Hoffmann La Roche AG · Expires 2020-01-22 · 6y expired

What this patent protects

Taselisib (GDC-0032) induces the degradation of mutant-pl 10 alpha protein. Methods for selecting patients with mutant P13K tumors for treatment with taselisib are described.

USPTO Abstract

Taselisib (GDC-0032) induces the degradation of mutant-pl 10 alpha protein. Methods for selecting patients with mutant P13K tumors for treatment with taselisib are described.

Drugs covered by this patent

Patent Metadata

Patent number
EP3598134A1
Jurisdiction
EP
Classification
—
Expires
2020-01-22
Drug substance claim
No
Drug product claim
No
Assignee
F Hoffmann La Roche AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.